

Screening ToxCast Chemicals in an Estrogen Receptor Transactivation Assay with Metabolic Competence

Chad Deisenroth
Center for Computational Toxicology and Exposure
deisenroth.chad@epa.gov

American Society for Cellular and Computational Toxicology 10th Annual Meeting
October 12th, 2021


Disclaimer: The views expressed are those of the author and do not necessarily reflect the views or policies of the U.S. Environmental Protection Agency.

21st-Century Challenges for 21st-Century Toxicology

National Research Council 2007 report calling for a genuine commitment to the reduction, refinement, and replacement of animal testing.

Key Questions for Implementation – Addressing Xenobiotic Metabolism

- “One of the challenges of developing an *in vitro* test system to evaluate toxicity is the current inability of cell assays to mirror metabolism in the integrated whole animal...”
- Methods to Predict Metabolism - How can adequate testing for metabolites in the high-throughput assays be ensured?
- Recommendations
 - Screening using computational approaches where possible.
 - Limited animal studies that focus on mechanism and specific metabolites.



EPA New Approach Methods Work Plan: Reducing Use of Animals in Chemical Testing





Five work plan objectives




Examples of information gaps

- Inadequate coverage of biological targets.
- Limited capability to address tissue- and organ-level effects.
- Lack of robust integrated approaches to testing and assessment (IATAs).
- Minimal capability for addressing xenobiotic metabolism in *in vitro* test systems.

The Next Generation Blueprint of Computational Toxicology at the U.S. Environmental Protection Agency






Extracellular Approach: The Alginate Immobilization of Metabolic Enzymes (AIME) Method




- **Liver Metabolism:** Hepatic S9 fractions derived from species of interest.
- **Alginate Hydrogel:** Widely used in a variety of pharmaceutical and biomedical applications due to high biocompatibility, low toxicity, and mild gelation by divalent cations.
- **AIME Method:** The AIME platform consists of custom 96- or 384-well microplate lids containing solid supports attached to encapsulated hepatic S9-alginate microspheres.


The Alginate Immobilization of Metabolic Enzymes Platform Retrofits an Estrogen Receptor Transactivation Assay With Metabolic Competence

Chad Deisenroth ^{*,1} Danica E. DeGroot ^{*,2} Todd Zurlinden ^{*}
Andrew Eicher,^{*} James McCord ^{*} Mi-Young Lee,^{†3} Paul Carmichael,[†] and
Russell S. Thomas ^{*}


AIME Metabolism Assay




Estrogen Receptor Transactivation Assay




ToxCast Pipeline



Toxboot Uncertainty Quantification



Rank Metabolism- dependent Bioactivity



Study Highlights

- Reprioritization of hazard based on metabolism-dependent bioactivity.
- Demonstrated utility of applying the AIME method for identification of false positive and false negative target assay effects.
- Enhanced *in vivo* concordance with the rodent uterotrophic bioassay.

Screening ToxCast Chemicals in an Estrogen Receptor Transactivation Assay with Metabolic Competence

Kristen Hopperstad¹, Danica E. DeGroot^{1,2}, Todd Zurlinden¹, Cassandra Brinkman¹, Russell S. Thomas¹, Chad Deisenroth^{1*}


Author Affiliations:

¹Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711, United States

²Current Address: Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration


Study Highlights

- **ToxCast Chemical Library:** Screen 768 chemicals for ER transactivation and viability.
- **Hazard Identification and Prioritization:** Identify and rank-order chemicals that are estrogenic and exhibit metabolism-dependent changes in bioactivity.
- **In Silico Prediction and Profiling:** Profile the common mechanistic routes of biotransformation and the identify of putative metabolites associated with the observed estrogenic effects.



Deployment of the 384-well AIME Method to the VM7Luc Estrogen Receptor Transactivation Assay

- **Target Bioassay:** OECD TG 455 - VM7Luc Estrogen Receptor Transactivation (ERTA) Assay
- **Metabolism Assay:** AIME system configured for rapid 384-well high-throughput screening.
- **Experimental Design:** Parallel evaluation of parent and metabolite effects.
- **Reference Chemicals:** Selected for ER target bioassay and the AIME metabolism assay.
 - ERTA: 17 β -Estradiol
 - AIME (activated): *trans*-Stilbene
 - AIME (inactivated): Ethylparaben
- **Performance Statistics:** Determined for ERTA and AIME assay.






Metabolism Negative

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
A	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
B	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
C	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
D	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
E	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
F	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
G	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
H	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
I	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
J	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
K	T58	T58	T58	T58	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
L	T58	T58	T58	T58	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
M	T58	T58	T58	T58	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
N	EP8	EP8	EP8	EP8	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
O	EP8	EP8	EP8	EP8	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
P	EP8	EP8	EP8	EP8	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002

Metabolism Positive



	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
A	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
B	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
C	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
D	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
E	DMSO	DMSO	DMSO	DMSO	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
F	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
G	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
H	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
I	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
J	E2	E2	E2	E2	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
K	T58	T58	T58	T58	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
L	T58	T58	T58	T58	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
M	T58	T58	T58	T58	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
N	EP8	EP8	EP8	EP8	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
O	EP8	EP8	EP8	EP8	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002
P	EP8	EP8	EP8	EP8	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002	200	129	79	45.7	25	12.5	4.36	1.12	0.125	0.002




ToxCast Pipeline Analysis

ToxCast Pipeline (TCPL) analysis run to identify estrogenic chemicals.


- 128/768 (17%) chemicals identified as bioactive for ER transactivation.
- The majority of chemicals (67%) are estrogenic with or without metabolism.
- A minor subset are bioactive exclusively with or without metabolism.




Metabolism Curve Shift Analysis



(E) - Anethole



TCPL - Standard
(Estrogenic effect)




TCPL - Metabolic Curve Shift
(Metabolism effect)

- Screening-level classification of activated and inactivated chemicals.
- Reprioritization of hazard based on empirical shift in metabolism-dependent bioactivity.

In Silico Metabolite Predictions with Chemical Transformation Simulator

The Chemical Transformation Simulator (CTS) is a web-based tool for predicting environmental and biological transformation pathways and physicochemical properties of organic chemicals.



- Chemical Speciation Workflow
- Physicochemical Properties Workflow
- Transformation Products Workflow



Features of CTS human phase I metabolite database:

- Parent and metabolite identifiers
- Physicochemical properties
- Associated routes of transformation
- Quantitative estimates for production and accumulation
- Metabolite probability classifications

Profiling Predicted Metabolites and Common Mechanisms of Biotransformation



Profiled novel chemicals associated with metabolism-dependent changes in ERTA bioactivity:

- Common mechanistic routes of transformation.
- The identify of putative metabolites associated with the observed estrogenic effects.

Profiling Predicted Metabolites and Common Mechanisms of Biotransformation

CASRN	Name	Classification	Metab Routes	Metab Global Accumulation	Metab Likelihood	Met_Neg Hitc	Met_Pos Hitc	Biotransformation	Metabolic Shift
94-26-8	Butylparaben	Parent	NA	NA	NA	1	0	inactivated	-167.3818927
99-96-7	4-Hydroxybenzoic acid	Metabolite	EsterHydrolysis	0.4988	LIKELY	1	0	inactivated	-167.3818927
71-36-3	1-Butanol	Metabolite	EsterHydrolysis	0.4256	LIKELY	1	0	inactivated	-167.3818927
1219-38-1	Octylparaben	Parent	NA	NA	NA	1	0	inactivated	-99.32932278
99-96-7	4-Hydroxybenzoic acid	Metabolite	EsterHydrolysis	0.4987	LIKELY	1	0	inactivated	-99.32932278
111-87-5	1-Octanol	Metabolite	EsterHydrolysis	0.4255	LIKELY	1	0	inactivated	-99.32932278
85-68-7	Benzyl butyl phthalate	Parent	NA	NA	NA	1	0	inactivated	-74.98383135
88-99-3	Phthalic acid	Metabolite	EsterHydrolysis	0.2469	LIKELY	1	0	inactivated	-74.98383135
100-51-6	Benzyl alcohol	Metabolite	EsterHydrolysis	0.3104	LIKELY	1	0	inactivated	-74.98383135
71-36-3	1-Butanol	Metabolite	EsterHydrolysis	0.3177	LIKELY	1	0	inactivated	-74.98383135
118-58-1	Benzyl salicylate	Parent	NA	NA	NA	1	1	inactivated	-43.94470165
69-72-7	Salicylic acid	Metabolite	EsterHydrolysis	0.4944	LIKELY	1	1	inactivated	-43.94470165
100-51-6	Benzyl alcohol	Metabolite	EsterHydrolysis	0.4135	LIKELY	1	1	inactivated	-43.94470165
103-41-3	Benzyl cinnamate	Parent	NA	NA	NA	1	0	inactivated	-39.07342352
621-82-9	Cinnamic acid	Metabolite	EsterHydrolysis	0.4789	LIKELY	1	0	inactivated	-39.07342352
100-51-6	Benzyl alcohol	Metabolite	EsterHydrolysis	0.4092	LIKELY	1	0	inactivated	-39.07342352
121-79-9	Propyl gallate	Parent	NA	NA	NA	1	1	inactivated	-24.05419192
149-91-7	Gallic acid	Metabolite	EsterHydrolysis	0.4989	LIKELY	1	1	inactivated	-24.05419192
71-23-8	1-Propanol	Metabolite	EsterHydrolysis	0.4259	LIKELY	1	1	inactivated	-24.05419192
118-55-8	Phenyl salicylate	Parent	NA	NA	NA	1	0	inactivated	-23.42557027
69-72-7	Salicylic acid	Metabolite	EsterHydrolysis	0.4997	LIKELY	1	0	inactivated	-23.42557027
108-95-2	Phenol	Metabolite	EsterHydrolysis	0.4997	LIKELY	1	0	inactivated	-23.42557027
81406-37-3	Fluroxypyr-meptyl	Parent	NA	NA	NA	1	0	inactivated	-18.89353032
69377-81-7	Fluroxypyr	Metabolite	EsterHydrolysis	0.457	LIKELY	1	0	inactivated	-18.89353032
123-96-6	2-Octanol	Metabolite	EsterHydrolysis	0.4848	LIKELY	1	0	inactivated	-18.89353032

Parent and Metabolite
Identifiers

Route of
Transformation


Accumulation
and Probability
Classification

In Vitro
Metabolism Data


Adaptation of the Alginate Immobilization of Metabolic Enzymes Platform to a 3D Bioprinting Approach for Metabolism-based High-throughput Screening



Lid vs Bioprinter Method



Phase 1 Metabolism



Goal: Adapt the AIME method to an automated 384-well approach using bioprinting.

Kristen Hopperstad, PhD
21st Century Challenges
Flash Poster # 10

Acknowledgements



Kristen Hopperstad
Danica DeGroot
Todd Zurlinden
Andrew Eicher
James McCord
Cassandra Brinkman
Woody Setzer
Katie Paul-Friedman
Madison Feshuk
Steve Simmons
Rusty Thomas



Paul Carmichael
Mi-Young Lee



Kamel Mansouri
Nicole Kleinstreuer
Steve Ferguson

